

# spironolactone

5mg/mL oral mixture\*

© Department of Health, Government of South Australia. All rights reserved.

# spironolactone

## 5mg/mL oral mixture\*

© Department of Health, Government of South Australia. All rights reserved.

### Dose and Indications

**Treatment of fluid overload states associated with hyperaldosteronism, including congestive heart failure and chronic lung disease (BPD); in combination with other diuretics**

#### Oral

1mg/kg every twelve hours

Dose may be increased up to 2mg/kg if required

### Preparation and Administration

#### Oral

The 5mg/mL solution contains:

Dose	2mg	4mg	6mg	8mg	10mg	12mg
Volume	0.4mL	0.8mL	1.2mL	1.6mL	2mL	2.4mL

\* 5mg/mL oral mixture is not commercially available however is manufactured at Women's & Children's Health Network Pharmacy and Flinders Medical Centre

Give with feeds to minimise gastrointestinal irritation

### Adverse Effects

#### Common

Hyperkalaemia, hyponatraemia, hypochloraemia (especially when combined with thiazide diuretics), vomiting

#### Infrequent

Gastrointestinal cramps, diarrhoea, drowsiness, gynaecomastia, mild acidosis, renal impairment

#### Rare

agranulocytosis, hepatotoxicity, rash, lichen planus, lupus-like syndrome, cutaneous vasculitis, urticaria, alopecia, chloasma, osteomalacia

# spironolactone

## 5mg/mL oral mixture\*

© Department of Health, Government of South Australia. All rights reserved.

### Monitoring

- > Electrolytes particularly potassium
- > Renal function
- > Periodic liver function tests and full blood counts if used long term

### Practice Points

- > As there is a high risk of hyperkalaemia in renal impairment, avoid if rapidly deteriorating or severe renal impairment

### Version control and change history

**PDS reference:** OCE use only

Version	Date from	Date to	Amendment
1.0	November 2012	current	Original version